NCT06434740View on ClinicalTrials.gov

A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Non-Small-Cell Lung Cancer
Interventions
RADIATION

Stereotactic Body Radiation Therapy，SBRT

The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.

DRUG

Puterizumab

Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER

NCT06434740 - A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC | Biotech Hunter | Biotech Hunter